Acute bronchitis is an inflammation of the large airways of the lung. It is a common clinical presentation to an emergency department, urgent care center, and primary care office. About 5% of adults have an episode of acute bronchitis each year. An estimated 90% of these seek medical advice for the same. In the United States, acute bronchitis is among the top ten most common illness among outpatients.
Acute bronchitis is caused by infection of the large airways commonly due to viruses and is usually self-limiting. Bacterial infection is uncommon. Approximately 95% of acute bronchitis in healthy adults are secondary to viruses. It can sometimes be caused by allergens, irritants, and bacteria. Irritants include smoke inhalation, polluted air inhalation, dust, among others.
Acute bronchitis is one of the common presentations in any healthcare setting. It is estimated that every year, 5% of the general population reports an episode of acute bronchitis, accounting for more than 10 million office visits yearly.  Like most of the viral diseases of the respiratory tract, acute bronchitis is commonly seen during the flu season. In the United States, flu season is common during autumn and winter. It can follow any viral upper respiratory infection (URI). The common pathogens are a respiratory syncytial virus, Influenza virus A and B, Parainfluenza, rhinovirus, and similar viruses.
Factor like a history of smoking, living in a polluted place, crowding, and a history of asthma, are all risk factors for acute bronchitis. In some people, acute bronchitis can be triggered by particular allergens like pollens, perfume, and vapors.
When the infection is bacterial, the isolated pathogens are usually the same as those responsible for community-acquired pneumonia, for example, Streptococcus pneumonia and Staphylococcus aureus.
Acute bronchitis is the result of acute inflammation of the bronchi secondary to various triggers, most commonly viral infection, allergens, pollutants, etc. Inflammation of the bronchial wall leads to mucosal thickening, epithelial-cell desquamation, and denudation of the basement membrane. At times, a viral upper respiratory infection can progress to infection of the lower respiratory tract resulting in acute bronchitis. 
An acute bronchitis patient presents with a productive cough, malaise, difficulty breathing, and wheezing. Usually, their cough is the predominant complaint and is clear or yellowish, although sometimes it can be purulent. Purulent sputum does not correlate with bacterial infection or antibiotic use.  Cough after acute bronchitis typically persists for 10 to 20 days but occasionally may last for 4 or more weeks. The median duration of cough after acute bronchitis is 18 days Paroxysms of cough accompanied by inspiratory whoop or post-tussive emesis should raise concerns for pertussis. A prodrome of URI symptoms like runny nose, sore throat, fever, and malaise are common. A low-grade fever may be present as well. High-grade fevers in the setting of acute bronchitis are unusual and further diagnostic workup is required.
On physical exam, lung auscultation may be significant for wheezing; pneumonia should be suspected when rales, rhonchi or egophony are appreciated. Tachycardia can be present reflecting fever as well as dehydration secondary to the viral illness. Rest of the systems are typically within normal limits.
Acute bronchitis is a clinical diagnosis based on history, past medical history, lung exam, and other physical findings. Oxygen saturation plays an important role in judging the severity of the disease along with the pulse rate, temperature, and respiratory rate. No further workup is needed if vital signs are normal, no exam findings suggestive of pneumonia. An exception to this rule is elderly patients >75 years old. Also, further workup is needed when pneumonia is suspected, clinical diagnosis is in question or in cases of high suspicion for influenza or pertussis.
Chest x-ray findings are not specific and are typically normal. Occasionally, chest x-ray demonstrates increased interstitial markings consistent with thickening of bronchial walls. A chest x-ray differentiates pneumonia from acute bronchitis when infiltrates are seen. Evidence-based guidelines from the American College of Chest Physicians(ACCP) recommends obtaining a CXR only when heart rate > 100/min, respiratory rate >24 breaths/min, oral body temperature > 38 degree C and chest examination findings of egophony or fremitus.
Complete blood count and chemistry may be ordered as a workup for fever. White blood count might be mildly elevated in some cases of acute bronchitis. Blood chemistry can reflect dehydration changes.
Routine use of rapid microbiological testing is not cost-effective and would not change management except during influenza season and in cases with high suspicion of pertussis or other bacterial infection. Gram stain and bacterial sputum cultures are specifically discouraged bacteria is rarely the causative agent.
Spirometry, when performed, demonstrates transient bronchial hyperresponsiveness in 40% of patients with acute bronchitis. Reversibility of FEV1 >15% is reported in 17% of patients.  Airflow obstruction and bronchial hyperresponsiveness typically resolve in 6 weeks.
Acute bronchitis is self-limiting and treatment is typically symptomatic and supportive therapy. For cough relief, nonpharmacological and pharmacological therapy should be offered. Nonpharmacological therapy includes hot tea, honey, ginger, throat lozenges, etc. No clinical trials evaluated the efficacy of these interventions. Antitussive agents like dextromethorphan, codeine or guaifenesin are frequently used in clinical practice to suppress cough based on their effectiveness in chronic bronchitis and studies on cough in common cold. No randomized trials exist to evaluate their effectiveness in acute bronchitis. Codeine should be avoided for the addictive potential. Data on the use of a mucolytic agent is conflicting.
Beta-agonists are routinely used in acute bronchitis patients with wheezing. Small Randomized control trials on beta agonists for cough in acute bronchitis had mixed results. A Cochrane review of five trials demonstrated no significant benefit of beta-agonists on daily cough except for a small benefit in a subgroup of patients with wheezing and airflow obstruction at baseline. A more recent Cochrane review demonstrated similar results 
Analgesic and antipyretic agents may be used to treat associated malaise, myalgia, and fever. Prednisone or other steroids can be given to help with the inflammation as well. Although there is not enough evidence showing their benefit, it is useful in patients with underlying chronic obstructive pulmonary disease (COPD) or asthma. Typically steroid is used as short-term burst therapy. Sometimes longer tapering dose of steroid might be warranted, especially in patients with underlying asthma or COPD. 
ACCP guidelines recommend against antibiotic use in simple acute bronchitis in otherwise healthy adults. A Cochrane review of nine randomized, controlled trials of antibiotic agents showed a minor reduction in the total duration of cough (0.6 days). The decrease in the number of days of illness was not significant per this review. Hence antibiotic use should be avoided in simple cases considering the cost of antibiotic, the growing global problem of antibiotic resistance and the possible side effects of antibiotic usage. Multiple other international medical societies recommend against antibiotic use in viral acute bronchitis. Despite these recommendations, a large proportion of patients with acute bronchitis are prescribed antibiotics. No data exist to justify the prospect of cough being less severe or less prolonged with antibiotic therapy. Antimicrobial therapy is recommended when a treatable pathogen is identified as with influenza or pertussis. In patients with influenza infection, oseltamivir or Zanamivir should be promptly started. Macrolides are the treatment of choice for Pertussis along with 5 days of isolation. It is interesting to note that whooping cough is only present in a minority of patients with pertussis.
Procalcitonin might be useful in deciding on antibiotic use when the diagnosis of acute bronchitis is uncertain. A meta-analysis demonstrated procalcitonin-guided antibiotic therapy reduced antibiotic exposure and improved survival. 
Lifestyle modification like smoking cessation and the avoidance of allergens and pollutants play an important role in the avoidance of recurrence and complications. Flu vaccine and pneumonia vaccine are especially recommended in special groups including adults older than 65, children younger than two years (older than six months), pregnant women, and residents of nursing homes and long-term care facilities. People with asthma, COPD, and other immunocompromised adults are also at higher risk of developing complications. Recurrence is seen in up to a third of the cases of acute bronchitis.
In summary, the data for the use of beta-agonists, steroids, and mucolytic agent, especially in patients with no underlying COPD and asthma, is lacking. Treatment should be guided by the individual response to them and reported benefit, as well as, weighing risk and benefit in each case.
Other causes of acute cough should be considered especially when a cough persists for longer than 3 weeks.
Sometimes secondary pneumonia can develop. This is usually indicated by worsening symptoms, productive cough and fever. In such cases, a chest x-ray is indicated. This is especially important in immunocompromised adults, elderly population, infants and newborns, and smokers. Pulmonary emboli should always be in differentials in a patient with a cough and shortness of breath. Sometimes aggressive coughing can lead to spontaneous pneumothorax and or spontaneous pneumomediastinum. Hence any acute worsening of symptoms usually requires a chest x-ray.
Acute bronchitis is a very common disorder that frequently presents to the emergency department or the primary provider's office. It is a very common cause of absenteeism from work/school. The condition is best managed by an interprofessional team that includes a primary care provider, a nurse, a pharmacist, and a pulmonologist. The key is coordinating patient education. The nursing staff should be tasked to work with patients to stop smoking and avoid exposure to secondhand smoke. The nurses should encourage individuals to get influenza and pneumococcal vaccines to reduce morbidity. The nurses should monitor patients for compliance and report back to the clinical team leader patients that are non-compliant with smoking cessation. In addition, the nurse and pharmacist should encourage hand washing to limit the spread of micro-organisms.
For those patients whose cough persists, the nurses should monitor for the possibility of atypical pneumonia or pneumonia that requires antibiotic therapy. In these cases, the nurse should arrange a follow-up visit with the clinical team for re-assessment. If an antibiotic is deemed necessary, the pharmacist should evaluate for drug-drug interaction and allergy prior to filling the prescription. If there are any concerns, the pharmacist should make the clinical team aware of potential problems before the drug is dispensed.
The outcomes of patients with acute bronchitis are good; however, it is a common reason for absenteeism from work. In some patients with underlying COPD and other lung problems, acute bronchitis can have high morbidity. Patients whose symptoms persist for more than six weeks need to be re-evaluated to ensure that the diagnosis is correct. (Level V)
|||Adams PF,Hendershot GE,Marano MA, Current estimates from the National Health Interview Survey, 1996. Vital and health statistics. Series 10, Data from the National Health Survey. 1999 Oct; [PubMed PMID: 15782448]|
|||Pulia M,Redwood R,May L, Antimicrobial Stewardship in the Emergency Department. Emergency medicine clinics of North America. 2018 Nov [PubMed PMID: 30297009]|
|||Saust LT,Bjerrum L,Siersma V,Arpi M,Hansen MP, Quality assessment in general practice: diagnosis and antibiotic treatment of acute respiratory tract infections. Scandinavian journal of primary health care. 2018 Oct 8 [PubMed PMID: 30296885]|
|||Tanner M,Karen Roddis J, Antibiotics for acute bronchitis. Nursing standard (Royal College of Nursing (Great Britain) : 1987). 2018 Feb 28 [PubMed PMID: 29488727]|
|||Braman SS, Chronic cough due to acute bronchitis: ACCP evidence-based clinical practice guidelines. Chest. 2006 Jan [PubMed PMID: 16428698]|
|||Kronman MP,Zhou C,Mangione-Smith R, Bacterial prevalence and antimicrobial prescribing trends for acute respiratory tract infections. Pediatrics. 2014 Oct [PubMed PMID: 25225144]|
|||Bai L,Su X,Zhao D,Zhang Y,Cheng Q,Zhang H,Wang S,Xie M,Su H, Exposure to traffic-related air pollution and acute bronchitis in children: season and age as modifiers. Journal of epidemiology and community health. 2018 May [PubMed PMID: 29440305]|
|||Wenzel RP,Fowler AA 3rd, Clinical practice. Acute bronchitis. The New England journal of medicine. 2006 Nov 16 [PubMed PMID: 17108344]|
|||Altiner A,Wilm S,Däubener W,Bormann C,Pentzek M,Abholz HH,Scherer M, Sputum colour for diagnosis of a bacterial infection in patients with acute cough. Scandinavian journal of primary health care. 2009 [PubMed PMID: 19242860]|
|||Ward JI,Cherry JD,Chang SJ,Partridge S,Lee H,Treanor J,Greenberg DP,Keitel W,Barenkamp S,Bernstein DI,Edelman R,Edwards K, Efficacy of an acellular pertussis vaccine among adolescents and adults. The New England journal of medicine. 2005 Oct 13 [PubMed PMID: 16221778]|
|||Smucny J,Becker L,Glazier R, Beta2-agonists for acute bronchitis. The Cochrane database of systematic reviews. 2006 Oct 18 [PubMed PMID: 17054140]|
|||Becker LA,Hom J,Villasis-Keever M,van der Wouden JC, Beta2-agonists for acute cough or a clinical diagnosis of acute bronchitis. The Cochrane database of systematic reviews. 2015 Sep 3 [PubMed PMID: 26333656]|
|||Smith DRM,Dolk FCK,Pouwels KB,Christie M,Robotham JV,Smieszek T, Defining the appropriateness and inappropriateness of antibiotic prescribing in primary care. The Journal of antimicrobial chemotherapy. 2018 Feb 1 [PubMed PMID: 29490061]|
|||Llor C,Bjerrum L, Antibiotic prescribing for acute bronchitis. Expert review of anti-infective therapy. 2016 Jul [PubMed PMID: 27219826]|
|||Smucny J,Fahey T,Becker L,Glazier R, Antibiotics for acute bronchitis. The Cochrane database of systematic reviews. 2004 Oct 18 [PubMed PMID: 15494994]|
|||Schuetz P,Wirz Y,Sager R,Christ-Crain M,Stolz D,Tamm M,Bouadma L,Luyt CE,Wolff M,Chastre J,Tubach F,Kristoffersen KB,Burkhardt O,Welte T,Schroeder S,Nobre V,Wei L,Bucher HC,Annane D,Reinhart K,Falsey AR,Branche A,Damas P,Nijsten M,de Lange DW,Deliberato RO,Oliveira CF,Maravić-Stojković V,Verduri A,Beghé B,Cao B,Shehabi Y,Jensen JS,Corti C,van Oers JAH,Beishuizen A,Girbes ARJ,de Jong E,Briel M,Mueller B, Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis. The Lancet. Infectious diseases. 2018 Jan [PubMed PMID: 29037960]|
|||Ngu S,Pervaiz S,Avula A,Chalhoub M, Rhinovirus-induced Rapidly Progressing Acute Respiratory Distress Syndrome in an Immunocompetent Host. Cureus. 2019 Feb 1 [PubMed PMID: 30989006]|
|||Soni P,Rai A,Aggarwal N,Kamholz S,Yoon T,Kupfer Y, Enterovirus-Human Rhinovirus: A Rare Cause of Acute Respiratory Distress Syndrome. Journal of investigative medicine high impact case reports. 2017 Jul-Sep [PubMed PMID: 28904980]|
|||Bettoncelli G,Blasi F,Brusasco V,Centanni S,Corrado A,De Benedetto F,De Michele F,Di Maria GU,Donner CF,Falcone F,Mereu C,Nardini S,Pasqua F,Polverino M,Rossi A,Sanguinetti CM, The clinical and integrated management of COPD. Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG. 2014 May 12 [PubMed PMID: 24820963]|
|||Palmer R,Anon JB,Gallagher P, Pediatric cough: what the otolaryngologist needs to know. Current opinion in otolaryngology [PubMed PMID: 21499103]|